TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36702574

Group type: EXPERIMENTAL
Intervention: Alopecia areata (AA) group
Number of subjects: 10491

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10491

Group type: COMPARATOR
Intervention: Control group (excluding those without recent GP consultation)
Number of subjects: 10491
Study: 36702771

Group type: EXPERIMENTAL
Intervention: Influenza A/California/04/2009/H1N1pdm-like virus inoculation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Baseline titers ≥40 by HAI
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Baseline titers ≥40 by MN
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Baseline titers <40 by HAI
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Baseline titers <40 by MN
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Every 2-fold increase in baseline HAI
Number of subjects: 76
Study: 36702822

Group type: EXPERIMENTAL
Intervention: Ramelteon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36702934

Group type: EXPERIMENTAL
Intervention: Acyclovir administered intravenously every 8 hours with a 1-hour infusion of 500 mg/m
Number of subjects: 1
Study: 36702949

Group type: EXPERIMENTAL
Intervention: Combined PD-1, BRAF and MEK inhibition
Number of subjects: 0
Study: 36703019

Group type: EXPERIMENTAL
Intervention: FLU-PRO Plus
Number of subjects: 845
Study: 36703025

Group type: EXPERIMENTAL
Intervention: Non-invasive ICP waveform analysis
Number of subjects: 0
Study: 36703104

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing breastfeeding intervention delivered by a trained lactation consultant in hospital, with continued support for up to 6 months postpartum.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 36703109

Group type: EXPERIMENTAL
Intervention: Tablet-based electronic decision-support system (EDSS) used by healthcare providers during ANC visits.
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Standard of care ANC services without EDSS.
Number of subjects: 1320
Study: 36703120

Group type: EXPERIMENTAL
Intervention: ADIVA (advanced double intravenous vasopressor automated system)
Number of subjects: 94

Group type: COMPARATOR
Intervention: DIVA (double intravenous vasopressor automated system)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ADIVA
Number of subjects: 94

Group type: COMPARATOR
Intervention: DIVA
Number of subjects: 94
Study: 36703160

Group type: EXPERIMENTAL
Intervention: Traffic-light front-of-pack environmental label
Number of subjects: 132

Group type: COMPARATOR
Intervention: No label condition
Number of subjects: 132
Study: 36703170

Group type: EXPERIMENTAL
Intervention: Kinect-based CIMT
Number of subjects: 29

Group type: COMPARATOR
Intervention: Therapist-based CIMT
Number of subjects: 29
Study: 36703196

Group type: EXPERIMENTAL
Intervention: Combined metabolic activators (CMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36703250

Group type: EXPERIMENTAL
Intervention: Immediate intervention (8-session emotion and self-regulation group intervention with daily app-based prompts)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Delayed intervention (received 5 months later)
Number of subjects: 120
Study: 36704479

Group type: EXPERIMENTAL
Intervention: Yiqi Fumai lyophilized injection (YQFM)
Number of subjects: 1200
Study: 36704634

Group type: EXPERIMENTAL
Intervention: rTMS (20 Hz over dorsolateral prefrontal cortex bilaterally)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AE (structured moderate-intensity aerobic exercise for 5 days/week over 2 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (only pharmacological therapy)
Number of subjects: 27
Study: 36704737

Group type: EXPERIMENTAL
Intervention: PSYCHOPATHY.COMP program (20-session individual intervention based on Compassion Focused Therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36704757

Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) intervention delivered weekly for 4 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) intervention
Number of subjects: 43
Study: 36704795

Group type: COMPARATOR
Intervention: Micronutrient-containing supplement including zinc, taken preconception and throughout pregnancy until birth.
Number of subjects: 0
Study: 36705050

Group type: EXPERIMENTAL
Intervention: Perioperative myocardial infarction/injury (PMI)
Number of subjects: 7754

Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events (MACEs)
Number of subjects: 7754

Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 7754

Group type: EXPERIMENTAL
Intervention: Extra-cardiac PMI
Number of subjects: 7754

Group type: EXPERIMENTAL
Intervention: Type 1 myocardial infarction (T1MI)
Number of subjects: 7754

Group type: EXPERIMENTAL
Intervention: Tachyarrhythmia
Number of subjects: 7754

Group type: EXPERIMENTAL
Intervention: Acute heart failure (AHF)
Number of subjects: 7754

Group type: EXPERIMENTAL
Intervention: Likely type 2 myocardial infarction (lT2MI)
Number of subjects: 7754

Group type: COMPARATOR
Intervention: No PMI
Number of subjects: 7754
Study: 36705266

Group type: EXPERIMENTAL
Intervention: PCV13 followed by PPSV23
Number of subjects: 128

Group type: COMPARATOR
Intervention: PPSV23 alone
Number of subjects: 128
Study: 36705268

Group type: EXPERIMENTAL
Intervention: COVID-positive pre-Delta cohort
Number of subjects: 2402

Group type: COMPARATOR
Intervention: COVID-negative participants
Number of subjects: 2402

Group type: EXPERIMENTAL
Intervention: COVID-positive participants across variants
Number of subjects: 2402
Study: 36705404

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccination
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccination after influenza vaccination
Number of subjects: 57
Study: 36705433

Group type: EXPERIMENTAL
Intervention: Integrated treatment for comorbid posttraumatic stress and substance use disorders
Number of subjects: 0
Study: 36705474

Group type: EXPERIMENTAL
Intervention: Intralesional PPD immunotherapy for the largest wart (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cryotherapy for all warts plus intralesional PPD for the largest wart (Group B)
Number of subjects: 50
Study: 36705526

Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks with enzalutamide 160 mg once daily and ADT
Number of subjects: 1232

Group type: COMPARATOR
Intervention: placebo every 3 weeks with enzalutamide 160 mg once daily and ADT
Number of subjects: 1232
Study: 36705559

Group type: EXPERIMENTAL
Intervention: Multicompartmental signal model for whole-body diffusion-weighted imaging (DWI)
Number of subjects: 0
Study: 36705566

Group type: EXPERIMENTAL
Intervention: 145 mg/day of nanocrystallized fenofibrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 15
Study: 36705644

Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel (ide-cel)
Number of subjects: 0
Study: 36705702

Group type: EXPERIMENTAL
Intervention: Probiotics+placebo
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Probiotics+fish oil
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Probiotics (combined probiotics+placebo and probiotics+fish oil)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Fish oil (combined fish oil+placebo and probiotics+fish oil)
Number of subjects: 439
Study: 36705710

Group type: EXPERIMENTAL
Intervention: Toric orthokeratology
Number of subjects: 30

Group type: COMPARATOR
Intervention: Soft toric multifocal lenses
Number of subjects: 30
Study: 36705923

Group type: EXPERIMENTAL
Intervention: Temozolomide plus interferon alfa
Number of subjects: 199

Group type: COMPARATOR
Intervention: Temozolomide
Number of subjects: 199
Study: 36705924

Group type: EXPERIMENTAL
Intervention: SGM-101 (10 mg) infused up to 5 days before index operation.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (CEACAM5-positive tumors).
Number of subjects: 10
Study: 36705941

Group type: COMPARATOR
Intervention: Sodium phenylbutyrate-taurursodiol (PB-TURSO), a combination of 3 g of PB and 1 g of TURSO given twice daily.
Number of subjects: 0

Group type: COMPARATOR
Intervention: AMX0035 (a sachet containing a fixed co-formulation of 3 g of PB and 1 g of TURSO given twice daily).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo) in the CENTAUR trial.
Number of subjects: 0
Study: 36705951

Group type: EXPERIMENTAL
Intervention: Novel digital digit-symbol substitution test (DDSST)
Number of subjects: 191
Study: 36705965

Group type: EXPERIMENTAL
Intervention: GlobalConsent
Number of subjects: 793

Group type: COMPARATOR
Intervention: AHEAD (attention-control)
Number of subjects: 793
Study: 36706123

Group type: EXPERIMENTAL
Intervention: Fibersol-2
Number of subjects: 92
Study: 36706322

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36706355

Group type: EXPERIMENTAL
Intervention: Decitabine and ipilimumab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ipilimumab monotherapy
Number of subjects: 48
Study: 36706362

Group type: EXPERIMENTAL
Intervention: iTHRIVE 365
Number of subjects: 32
Study: 36706364

Group type: EXPERIMENTAL
Intervention: Tenofovir, lamivudine/emtricitabine, and dolutegravir (TLD)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enhanced adherence counseling
Number of subjects: 62
Study: 36706435

Group type: EXPERIMENTAL
Intervention: Health Insurance Education Program
Number of subjects: 0
Study: 36706645

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily during NACT
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo during NACT
Number of subjects: 188
Study: 36706655

Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg/day fixed starting dose or individualized starting dose according to baseline body weight and platelet count)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Individualized starting dose (ISD) of niraparib
Number of subjects: 316

Group type: COMPARATOR
Intervention: Fixed starting dose of niraparib
Number of subjects: 316
Study: 36706658

Group type: EXPERIMENTAL
Intervention: Preoperative baseline EEG recordings (focused wakefulness and relaxed wakefulness)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Baseline EEG recordings during relaxed and focused wakefulness
Number of subjects: 89
Study: 36706675

Group type: EXPERIMENTAL
Intervention: In-person counselling (45-70 minutes, two sessions over three months) with interim monthly booster phone calls (live call arm)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: In-person counselling (45-70 minutes, two sessions over three months) with twice-weekly automated booster sessions (technology arm)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Live call arm
Number of subjects: 269

Group type: COMPARATOR
Intervention: Technology arm
Number of subjects: 269
Study: 36706754

Group type: EXPERIMENTAL
Intervention: Lentivirus-based gene therapy
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Targeted treatments to protect HSCs
Number of subjects: 4
Study: 36706778

Group type: EXPERIMENTAL
Intervention: Chlorfenapyr-pyrethroid LLINs
Number of subjects: 216289

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen-pyrethroid LLINs
Number of subjects: 216289

Group type: COMPARATOR
Intervention: Pyrethroid-only LLINs (reference group)
Number of subjects: 216289
Study: 36706959

Group type: EXPERIMENTAL
Intervention: Pseudoprogression (PSP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: True progression (TP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tumor volume (TV) at relapse
Number of subjects: 180
Study: 36706958

Group type: EXPERIMENTAL
Intervention: Dose-escalated radiotherapy to the whole primary tumour
Number of subjects: 150

Group type: COMPARATOR
Intervention: Dose-escalated radiotherapy to a PET-defined subvolume
Number of subjects: 150
Study: 36707080

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Number of subjects: 6100

Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (combined clopidogrel and aspirin for days 1-21, then aspirin placebo and clopidogrel for days 22-90) plus delayed intensive statin therapy (atorvastatin placebo for days 1-3, followed by 40 mg per day of atorvastatin for days 4-90)
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy (combination of clopidogrel placebo with aspirin for 90 days) plus immediate intensive statin therapy (atorvastatin at a dose of 80 mg daily for the first 21 days, then 40 mg daily for days 22-90)
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy plus delayed intensive statin therapy
Number of subjects: 6100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 6100
Study: 36707111

Group type: EXPERIMENTAL
Intervention: Intradialytic inspiratory muscle training (IMT) at 30% of maximal inspiratory pressure
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intradialytic inspiratory muscle training (IMT) at 50% of maximal inspiratory pressure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham intradialytic inspiratory muscle training (sham-IMT) at 10% of maximal inspiratory pressure
Number of subjects: 36
Study: 36707127

Group type: EXPERIMENTAL
Intervention: Reduced DLCO in current smokers
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Reduced DLCO in former smokers
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Reduced DLCO in never smokers
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Clinical implications of reduced DLCO
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Risk factors for low DLCO
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: CT findings in smokers with reduced DLCO
Number of subjects: 405
Study: 36707482

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by robot-assisted minimally invasive esophagectomy (RAMIE) with three-field lymphadenectomy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive esophagectomy (RAMIE)
Number of subjects: 29
Study: 36707489

Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong with breathing meditation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 30
Study: 36707656

Group type: EXPERIMENTAL
Intervention: Fully liquid presentation of MenACWY-CRM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed presentation of MenACWY-CRM
Number of subjects: 0
Study: 36707675

Group type: EXPERIMENTAL
Intervention: Students
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-students
Number of subjects: 0
Study: 36707764

Group type: EXPERIMENTAL
Intervention: MRE diet for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Habitual diet (HAB)
Number of subjects: 0
Study: 36707778

Group type: EXPERIMENTAL
Intervention: Increasing PrEP (iPrEP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 40
Study: 36707808

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) 35 mg/m²
Number of subjects: 914
Study: 36707841

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 20% hypertonic saline solution (HSS) to maintain blood sodium level between 150 and 155 mmol/L for at least 48 hours.
Number of subjects: 322

Group type: COMPARATOR
Intervention: Standard of care as recommended by the latest Brain Trauma foundation guidelines.
Number of subjects: 322
Study: 36707852

Group type: EXPERIMENTAL
Intervention: Perineal wound infection
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intact anal sphincter
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: OASIS
Number of subjects: 73
Study: 36707909

Group type: EXPERIMENTAL
Intervention: Linkage navigation plus clinician referral
Number of subjects: 280

Group type: COMPARATOR
Intervention: Clinician referral alone
Number of subjects: 280
Study: 36708012

Group type: EXPERIMENTAL
Intervention: Women with obesity
Number of subjects: 42

Group type: COMPARATOR
Intervention: Women without obesity
Number of subjects: 42
Study: 36708187

Group type: EXPERIMENTAL
Intervention: SPIN-CHAT Program
Number of subjects: 30
Study: 36708371

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketoconazole (wild-type cases)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ketoconazole (FOXL2 mutation cases)
Number of subjects: 6
Study: 36708381

Group type: EXPERIMENTAL
Intervention: Balneotherapy by immersion in 42℃ thermal-mineral water
Number of subjects: 137

Group type: COMPARATOR
Intervention: Regular outpatient care
Number of subjects: 137
Study: 36708469

Group type: EXPERIMENTAL
Intervention: ixazomib-dexamethasone
Number of subjects: 168

Group type: COMPARATOR
Intervention: physician's choice
Number of subjects: 168
Study: 36708539

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Non-CCB users
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: CCB use
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: CCB use in single antihypertensive agent
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: CCB use in > 1 antihypertensive agent
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: CCB use in controlled hypertension
Number of subjects: 392
Study: 36708608

Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomedical, relational, and socio-political models of peer support
Number of subjects: 0
Study: 36708650

Group type: EXPERIMENTAL
Intervention: Propolis (4 capsules of 100 mg/day for two months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (4 capsules of 100 mg/day for two months)
Number of subjects: 41
Study: 36708691

Group type: EXPERIMENTAL
Intervention: Bova score
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: ESC model
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: PEITHO-3 model
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: modified FAST score
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: CT RV enlargement
Number of subjects: 848
Study: 36708732

Group type: EXPERIMENTAL
Intervention: High-dose protein (≥2·2 g/kg per day)
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Usual dose protein (≤1·2 g/kg per day)
Number of subjects: 1301
Study: 36708734

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate treatment over 2 years
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo treatment over 2 years
Number of subjects: 240
Study: 36708738

Group type: EXPERIMENTAL
Intervention: CIS43LS 1 mg/kg intravenously
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CIS43LS 5 mg/kg intravenously
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CIS43LS 10 mg/kg intravenously
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CIS43LS 5 mg/kg subcutaneously
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CIS43LS 10 mg/kg subcutaneously
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no CIS43LS)
Number of subjects: 31
Study: 36708911

Group type: EXPERIMENTAL
Intervention: Lenient postoperative activity instructions
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Strict postoperative activity instructions
Number of subjects: 1250
Study: 36708956

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day
Number of subjects: 842

Group type: COMPARATOR
Intervention: Vortioxetine 5-20 mg/day
Number of subjects: 842

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 842

Group type: COMPARATOR
Intervention: Agomelatine 25-50 mg/day
Number of subjects: 842
Study: 36708966

Group type: EXPERIMENTAL
Intervention: Multimedia tablet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Paper handout
Number of subjects: 59
Study: 36709053

Group type: EXPERIMENTAL
Intervention: Lung health check invitation
Number of subjects: 95397

Group type: EXPERIMENTAL
Intervention: Re-invitation of non-responders
Number of subjects: 95397

Group type: EXPERIMENTAL
Intervention: Overall uptake
Number of subjects: 95397

Group type: EXPERIMENTAL
Intervention: Age group comparison
Number of subjects: 95397

Group type: EXPERIMENTAL
Intervention: Deprivation comparison
Number of subjects: 95397

Group type: EXPERIMENTAL
Intervention: Ethnicity comparison
Number of subjects: 95397

Group type: EXPERIMENTAL
Intervention: Smoking status comparison
Number of subjects: 95397

Group type: EXPERIMENTAL
Intervention: Ethnicity subgroup analysis
Number of subjects: 95397
Study: 36709074

Group type: EXPERIMENTAL
Intervention: cAd3-Marburg vaccine (1×10^11 viral particles)
Number of subjects: 40
Study: 36709073

Group type: EXPERIMENTAL
Intervention: Momelotinib (200 mg orally once per day)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Danazol (300 mg orally twice per day)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 195

Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 195
Study: 36709271

Group type: EXPERIMENTAL
Intervention: Palliative sedation
Number of subjects: 0
Study: 36709275

Group type: EXPERIMENTAL
Intervention: BI 425809 2 mg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: BI 425809 5 mg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: BI 425809 10 mg
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: BI 425809 25 mg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: All BI 425809 treatment groups
Number of subjects: 610
Study: 36709386

Group type: EXPERIMENTAL
Intervention: Cancer remission group
Number of subjects: 477

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 477
Study: 36709533

Group type: EXPERIMENTAL
Intervention: Agalsidase beta treatment
Number of subjects: 176
Study: 36709563

Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies implemented to address challenges
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General linear and mixed effects modeling
Number of subjects: 0
Study: 36709637

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (3×60 min sessions per week at 60 to 80% peak heart rate for 16 weeks)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 135